Redeye comments on Isofol’s update that the second dose level in its ongoing phase Ib/II study has been completed successfully, with 200 mg/m² shown to be safe and well tolerated. We view the clearance to proceed to 300 mg/m² as an important step in validating the revised dosing strategy for arfolitixorin, supported by preclinical data indicating a dose-response relationship.
LÄS MER
